DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* TROPHOS *


 

1999 - Méditerranée
Marseille
www.trophos.com

 

Discovery, Drugs
Key words: Embryonic neurones, Parkinson's diseases, Huntington's diseases, Cardiac ischemia, IRIstop
Mission: to develop drugs to prevent neuronal loss in patients with neurodegenerative diseases, based on proprietary screening system employing sick neurons (focused in 2009, onto neuroprotection and cardioprotection)
Clients: Prescribers
info@trophos.com

Age: 18 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Placet (Christine) [Sup de Co (Marseille), ex-Ernst & Young]
Sc.Dir.-CSO: Pruss (Rebecca) [Ph.D., ex-Sanofi-Synthélabo]
Med.Dir.-CMO: Abitbol (Jean-Louis) [M.D., ex-Parke Davis, Pfizer, Pierre Fabre]
Fin.Dir.-CFO:
BusDev: Harris (Stephen) [Ph.D., ex-GSK]
Financers (Hist.): Société Générale Assets Management (SGAM), Turenne Capital Partners, Viveris Management, SOFIPACA, SOFIMAC OTC Asset Management, CM-CIC Asset Management, Blue Medical, AFM (French Muscular Dystrophy Association), Innoveris, business angels

Turnover (M€) : 0.01 (2009), 0.27 (2008), 0.68 (2006)
Total funding (M€) : 68.0
Last funding (M€) : 10.0
Focus : Multiple
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .10 Clinical trial (Phase II) on TRO40303, in acute myocardial infarction (beginning) CLIN [13 years]
2012 .06 Nomination : Christine Placet (previously CFO, since 2004), as CEO (Damian Marron on leave) ORGN [13 years]
2010 .12 Financing : leader of new MitoCare consortium awarded 6 M€ by EU for POC study of novel cardioprotective compound, TRO40303 RFIN [11 years]
2010 .10 Clinical trial (Phase I) on TRO40303, in myocardial infarction (beginning), ended in February 2011 CLIN [11 years]
2010 .09 Financing : 10.0 M€ from Actelion (Switzerland) against minority share, with rights of full acquisition up to 2012 depending on phase III clinical results of olesoxime RFIN [11 years]
2010 .03 Clinical trial (phase III) for olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) (end recruitment, results in December 2012, not superior to riluzole alone) CLIN [11 years]
2010 .03 Launch : new web site on Charcot disease for patients and health professionals at MitoTarget MKTG [11 years]
2009 .09 Clinical trial planned, after first preclinical trial results on TRO40303, a novel TSPO ligand, significantly reducing myocardial infarct size CLIN [10 years]
2009 .03 Financing (grant over 3 years) : 6.7 M€ by Association Française contre les Myopathies (AFM), for further clinical development of lead drug candidate olesoxime (TRO19622) as a treatment for Spinal Muscular Atrophy RFIN [10 years]
2008 .12 Financing (no interest loan) : 6.0 M€, by the European Commission, to boost TRO19622 programs for ALS, within Trophos led consortium (Mitotarget) DEBT [9 years]
2008 .06 Nomination : Damian Marron as CEO, replacing co-founder Antoine Béret [born 1944, ex-Immunotech] who retires ORGN [9 years]
2008 .02 Financing (no interest loan) : 1.0 M€, by ANR, to support the project named IRIstop DEBT [9 years]
2007 .09 3rd round-financing : 8.5 M€, led by OTC Asset Management with CM-CIC Asset Management and previous shareholders RFINC [8 years]
2003 .04 2nd round-financing : 6.4 M€, led by Innoveris and previous shareholders RFINB [4 years]
1999 .01 Company founded by Antoine Béret (CEO), Michel Deléage (venture capitalist, died in 2011), and 3 scientists (as consultants) ORGF [0 year]

Actualisation / Updating: 27-Dec-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende